Teva says its Phase II trial for the experimental lupus drug edratide failed to hit its primary endpoint. The weekly therapy failed to cut the rate of disease activity after 26 weeks of treatments. Teva says it will make a final determination on how to proceed after it crunches the numbers for secondary endpoints. The drug appeared safe and was well tolerated.
- check out the release for more info